Cardinal Health stock: UBS raises target from USD 280.00 to USD 295.00

Published on 10/20/2026 at 16:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue rose 14.21 percent in fiscal 2026. Cardinal Health stock costs EUR 225.60 on October 20, 2026, up 1.08 percent versus Tradegate.

Analyst target and reporting date

UBS raised its Cardinal Health target from USD 280.00 to USD 295.00 on October 16, 2026.
Fiscal 2026 revenue reached USD 254.25 billion, up 14.21 percent from fiscal 2025.
Cardinal Health stock costs EUR 225.60 at Lang & Schwarz on October 20, 2026 at 4:36 p.m. CEST, 1.08 percent above the Tradegate close.
Cardinal Health plans to report first-quarter fiscal 2027 results on November 5, 2026.

Isometrische 3D-Illustration der Pharma-Lieferkette von Produktion bis Apotheke — Isometrisches 3D-Diagramm der Lieferkette von Cardinal Health Inc. – Medizinprodukte ISIN US14149Y1082, Illustration mit AI erstellt.

UBS raised its price target for Cardinal Health from USD 280.00 to USD 295.00 on October 16, 2026, while maintaining a Buy rating, according to Yahoo Finance. Cardinal Health stock was trading at EUR 225.60 at Lang & Schwarz on October 20, 2026 at 4:36 p.m. CEST, up 1.08 percent versus the Tradegate close of October 19, 2026 at EUR 223.20.

Fiscal revenue reached USD 254.25 billion

Cardinal Health reported USD 254.25 billion in revenue for fiscal 2026, compared with USD 222.58 billion in fiscal 2025, a 14.21 percent increase. Diluted earnings per share rose to USD 7.23 from USD 6.45 over the same fiscal-year comparison, according to Yahoo Finance.

What does the target mean?

The USD 295.00 UBS target stands 16.05 percent above Cardinal Health's USD 254.21 NYSE price at 10:47 a.m. ET on October 20, 2026. The target therefore sits above the latest US trading price even as the euro quotation is only 1.08 percent above its Tradegate close.

Stock remains near its yearly high

Cardinal Health's NYSE price stood at USD 254.21 on October 20, 2026, while its 52-week range was USD 155.84 to USD 258.30 as of October 19, 2026. The stock was 1.71 percent below that high, and its year-to-date gain was 24.11 percent. Volume reached 3,052,881 shares on October 19, 2026, according to Yahoo Finance.

Valuation and reporting date

Cardinal Health had a market capitalization of USD 58.9 billion and a trailing price-to-earnings ratio of 35.14 on October 20, 2026. The company is scheduled to report first-quarter fiscal 2027 results on November 5, 2026, before the NYSE opens, according to Yahoo Finance.

Comparison with peers

Cardinal Health: up 0.62 percent in USD terms on October 20, 2026, P/E 35.14, market capitalization USD 58.9 billion.

McKesson Corporation (NYSE, USD): up 0.72 percent on October 20, 2026, P/E 27.23, market capitalization USD 118.7 billion.

Cencora (NYSE, USD): up 0.27 percent on October 20, 2026, P/E 25.33, market capitalization USD 65.1 billion.

Price sets the near-term frame

For investors, the key contrast is the gap between the UBS target and Cardinal Health's latest NYSE price, alongside a valuation multiple above those of McKesson and Cencora. The next scheduled earnings date gives the market a defined checkpoint for the fiscal 2027 outlook.

Cardinal Health was trading at EUR 225.60 at Lang & Schwarz on October 20, 2026 at 4:36 p.m. CEST, up 1.08 percent versus the Tradegate close of October 19, 2026 at EUR 223.20. The further course of trading is shown by the continuously updated real-time quote of Cardinal Health stock.